Stock Analysis
- United Kingdom
- /
- Medical Equipment
- /
- AIM:DEMG
Deltex Medical Group Full Year 2023 Earnings: UK£0.001 loss per share (vs UK£0.002 loss in FY 2022)
Deltex Medical Group (LON:DEMG) Full Year 2023 Results
Key Financial Results
- Revenue: UK£1.78m (down 28% from FY 2022).
- Net loss: UK£1.28m (loss widened by 12% from FY 2022).
- UK£0.001 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Deltex Medical Group shares are down 7.0% from a week ago.
Risk Analysis
Before you take the next step you should know about the 5 warning signs for Deltex Medical Group (4 are concerning!) that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether Deltex Medical Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:DEMG
Deltex Medical Group
Manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally.
Medium with mediocre balance sheet.